Jeffrey B Raskin1, Michael A Kamm2, M Mazen Jamal3, Juan Márquez4, Ehud Melzer5, Robert E Schoen6, Tibor Szalóki7, Karen Barrett8, Paul Streck9. 1. University of Miami Miller School of Medicine, Miami, Florida. Electronic address: JRaskin@med.miami.edu. 2. St Vincent's Hospital and University of Melbourne, Melbourne, Australia; Imperial College, London, UK. 3. VA Long Beach Healthcare System, Long Beach, California. 4. Clínica Las Américas, Medellin, Colombia. 5. Department of Gastroenterology and Liver Disease, Kaplan Medical Center, Rehovot, Israel. 6. Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania. 7. Department of Gastroenterology, Ödön Jávorszky Hospital, Vác, Hungary. 8. Shire, Basingstoke, UK. 9. Shire, Wayne, Pennsylvania.
Abstract
BACKGROUND & AIMS: No therapy has been proven to prevent the recurrence of diverticulitis. Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease. We investigated the efficacy of mesalamine in preventing recurrence of diverticulitis in 2 identical but separate phase 3, randomized, double-blind, placebo-controlled, multicenter trials (identical confirmatory trials were conducted for regulatory reasons). METHODS: We evaluated the efficacy and safety of multimatrix mesalamine vs placebo in the prevention of recurrent diverticulitis in 590 (PREVENT1) and 592 (PREVENT2) adult patients with ≥1 episodes of acute diverticulitis in the previous 24 months that resolved without surgery. Patients received mesalamine (1.2 g, 2.4 g, or 4.8 g) or placebo once daily for 104 weeks. The primary end point was the proportion of recurrence-free patients at week 104. Diverticulitis recurrence was defined as surgical intervention at any time for diverticular disease or presence of computed tomography scan results demonstrating bowel wall thickening (>5 mm) and/or fat stranding consistent with diverticulitis. For a portion of the study, recurrence also required the presence of abdominal pain and an increase in white blood cells. RESULTS:Mesalamine did not reduce the rate of diverticulitis recurrence at week 104. Among patients in PREVENT1, 53%-63% did not have disease recurrence, compared with 65% of those given placebo. Among patients in PREVENT2, 59%-69% of patients did not have disease recurrence, compared with 68% of those given placebo. Mesalamine did not reduce time to recurrence, and the proportions of patients requiring surgery were comparable among treatment groups. No new adverse events were identified with mesalamine administration. CONCLUSIONS:Mesalamine was not superior to placebo in preventing recurrent diverticulitis. Mesalamine is not recommended for this indication. ClinicalTrials.gov ID: NCT00545740 and NCT00545103.
RCT Entities:
BACKGROUND & AIMS: No therapy has been proven to prevent the recurrence of diverticulitis. Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease. We investigated the efficacy of mesalamine in preventing recurrence of diverticulitis in 2 identical but separate phase 3, randomized, double-blind, placebo-controlled, multicenter trials (identical confirmatory trials were conducted for regulatory reasons). METHODS: We evaluated the efficacy and safety of multimatrix mesalamine vs placebo in the prevention of recurrent diverticulitis in 590 (PREVENT1) and 592 (PREVENT2) adult patients with ≥1 episodes of acute diverticulitis in the previous 24 months that resolved without surgery. Patients received mesalamine (1.2 g, 2.4 g, or 4.8 g) or placebo once daily for 104 weeks. The primary end point was the proportion of recurrence-free patients at week 104. Diverticulitis recurrence was defined as surgical intervention at any time for diverticular disease or presence of computed tomography scan results demonstrating bowel wall thickening (>5 mm) and/or fat stranding consistent with diverticulitis. For a portion of the study, recurrence also required the presence of abdominal pain and an increase in white blood cells. RESULTS:Mesalamine did not reduce the rate of diverticulitis recurrence at week 104. Among patients in PREVENT1, 53%-63% did not have disease recurrence, compared with 65% of those given placebo. Among patients in PREVENT2, 59%-69% of patients did not have disease recurrence, compared with 68% of those given placebo. Mesalamine did not reduce time to recurrence, and the proportions of patients requiring surgery were comparable among treatment groups. No new adverse events were identified with mesalamine administration. CONCLUSIONS:Mesalamine was not superior to placebo in preventing recurrent diverticulitis. Mesalamine is not recommended for this indication. ClinicalTrials.gov ID: NCT00545740 and NCT00545103.
Authors: Cesare Cremon; Marilia Carabotti; Rosario Cuomo; Fabio Pace; Paolo Andreozzi; Maria Raffaella Barbaro; Bruno Annibale; Giovanni Barbara Journal: United European Gastroenterol J Date: 2019-04-20 Impact factor: 4.623
Authors: G A Binda; R Cuomo; A Laghi; R Nascimbeni; A Serventi; D Bellini; P Gervaz; B Annibale Journal: Tech Coloproctol Date: 2015-09-16 Impact factor: 3.781
Authors: Antonio Tursi; Giovanni Brandimarte; Francesco Di Mario; Maria L Annunziata; Mauro Bafutto; Maria A Bianco; Raffaele Colucci; Rita Conigliaro; Silvio Danese; Rudi De Bastiani; Walter Elisei; Ricardo Escalante; Roberto Faggiani; Luciano Ferrini; Giacomo Forti; Giovanni Latella; Maria G Graziani; Enio C Oliveira; Alfredo Papa; Antonio Penna; Piero Portincasa; Kjetil Søreide; Antonio Spadaccini; Paolo Usai; Stefanos Bonovas; Carmelo Scarpignato; Marcello Picchio; Piera G Lecca; Costantino Zampaletta; Claudio Cassieri; Alberto Damiani; Kari F Desserud; Serafina Fiorella; Rosario Landi; Elisabetta Goni; Maria A Lai; Flavia Pigò; Gianluca Rotondano; Giuseppe Schiaccianoce Journal: United European Gastroenterol J Date: 2015-11-13 Impact factor: 4.623